Vivos Therapeutics Inc (VVOS)

$0.45 -0.05 (-9.05%)
Market Cap 6.30M
Revenue (ttm) 17.44M
Net Income (ttm) -21.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -121.39%
Debt to Equity Ratio -6.08
Volume 400,600
Avg Vol 2,019,394
Day's Range N/A - N/A
Shares Out 13.90M
Stochastic %K 42%
Beta 6.16
Analysts Sell
Price Target $2.45

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test...

Industry: Medical Devices
Sector: Healthcare
Phone: 866 908 4867
Address:
7921 Southpark Plaza, Suite 210, Littleton, United States
Giovannirs3
Giovannirs3 Jul. 4 at 12:58 PM
$VVOS 🤡
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:26 AM
$VVOS 👀👌👌👍🤣🤣🤗👎👍👍
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:25 AM
$VVOS 🤣🤣🤣🤣🤣🤣🤣🤗🤗🤗🤗
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:25 AM
$VVOS 👇👇🤣🤣🤣🤣🤣🤣🤣🚆🚆🚆🚆🚆
0 · Reply
kemsma62
kemsma62 Jul. 3 at 2:01 PM
$VVOS 🚀🧨🔥 The future belongs to $VVOS!
1 · Reply
Giovannirs3
Giovannirs3 Jul. 3 at 8:46 AM
$VVOS 💔
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡🤡🤡🤡🤡9️⃣❤️
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡🤡👎
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 👎
0 · Reply
Latest News on VVOS
Vivos Therapeutics says Vida oral appliance improves insomnia in study

2026-06-30T13:35:46.000Z - 4 days ago

Vivos Therapeutics says Vida oral appliance improves insomnia in study

Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Jun 30, 2026, 8:45 AM EDT - 4 days ago

Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Jun 22, 2026, 8:30 AM EDT - 12 days ago

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics intends to file registration statement for rights offering

2026-06-11T12:55:08.000Z - 23 days ago

Vivos Therapeutics intends to file registration statement for rights offering

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Jun 11, 2026, 8:30 AM EDT - 23 days ago

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics enters pact with South Palm Cardiovascular Associates

2026-06-10T13:18:43.000Z - 24 days ago

Vivos Therapeutics enters pact with South Palm Cardiovascular Associates

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Jun 10, 2026, 9:03 AM EDT - 24 days ago

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics Transcript: WTR Insights Conference: Powered by The Small Cap Showcase

Jun 9, 2026, 11:30 AM EDT - 25 days ago

Vivos Therapeutics Transcript: WTR Insights Conference: Powered by The Small Cap Showcase

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Jun 8, 2026, 1:39 PM EDT - 26 days ago

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Jun 5, 2026, 8:45 AM EDT - 4 weeks ago

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

2026-05-20T20:22:09.000Z - 6 weeks ago

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

May 20, 2026, 4:10 PM EDT - 6 weeks ago

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Vivos Therapeutics Quarterly report: Q1 2026

May 20, 2026, 4:00 PM EDT - 6 weeks ago

Vivos Therapeutics Quarterly report: Q1 2026

Vivos Therapeutics Earnings release: Q1 2026

May 20, 2026, 4:00 PM EDT - 6 weeks ago

Vivos Therapeutics Earnings release: Q1 2026

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

May 9, 2026, 11:53 AM EDT - 2 months ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ACTU ATAI

Vivos Therapeutics Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Vivos Therapeutics Registration statement: Registration filing

Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

2026-04-17T13:52:17.000Z - 2 months ago

Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global

2026-04-17T12:43:47.000Z - 2 months ago

Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global

Vivos Therapeutics Earnings Call Transcript: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 2 months ago

Vivos Therapeutics Earnings Call Transcript: Q4 2025

Vivos Therapeutics Earnings release: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 2 months ago

Vivos Therapeutics Earnings release: Q4 2025

Vivos Therapeutics Annual report: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 2 months ago

Vivos Therapeutics Annual report: Q4 2025

Vivos Therapeutics Reports Full Year 2025 Financial Results

Apr 15, 2026, 4:20 PM EDT - 2 months ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Apr 15, 2026, 8:45 AM EDT - 2 months ago

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Apr 7, 2026, 8:45 AM EDT - 3 months ago

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Mar 26, 2026, 8:45 AM EDT - 3 months ago

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics’ oral medical devices proven to enhance airways

2026-03-17T13:00:18.000Z - 3 months ago

Vivos Therapeutics’ oral medical devices proven to enhance airways

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Mar 17, 2026, 8:45 AM EDT - 3 months ago

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Vivos Therapeutics Registration statement: Registration Filing

Feb 17, 2026, 7:00 AM EST - 4 months ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics files to sell 3.96M shares of common stock for holders

2026-02-17T11:15:45.000Z - 4 months ago

Vivos Therapeutics files to sell 3.96M shares of common stock for holders

Vivos, SoundHealth collaborate to expand access to SoundHealth’s technology

2026-02-05T13:50:40.000Z - 5 months ago

Vivos, SoundHealth collaborate to expand access to SoundHealth’s technology

Vivos Therapeutics signs 12-part media series with New to the Street

2026-02-05T13:50:12.000Z - 5 months ago

Vivos Therapeutics signs 12-part media series with New to the Street

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Feb 5, 2026, 8:45 AM EST - 5 months ago

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Jan 20, 2026, 5:31 PM EST - 5 months ago

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Vivos Therapeutics announces exercise of warrants for $4.64M gross proceeds

2026-01-16T13:10:49.000Z - 6 months ago

Vivos Therapeutics announces exercise of warrants for $4.64M gross proceeds

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Jan 16, 2026, 8:00 AM EST - 6 months ago

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Vivos Therapeutics Transcript: Fireside Chat

Dec 16, 2025, 11:00 AM EST - 7 months ago

Vivos Therapeutics Transcript: Fireside Chat

Vivos Therapeutics opens sleep center in Auburn Hills, Michigan

2025-12-16T13:50:29.000Z - 7 months ago

Vivos Therapeutics opens sleep center in Auburn Hills, Michigan

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Dec 16, 2025, 8:45 AM EST - 7 months ago

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Vivos Therapeutics Earnings Call Transcript: Q3 2025

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Earnings Call Transcript: Q3 2025

Vivos Therapeutics Earnings release: Q3 2025

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Earnings release: Q3 2025

Vivos Therapeutics Quarterly report: Q3 2025

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Quarterly report: Q3 2025

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

2025-11-19T21:30:18.000Z - 8 months ago

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Nov 19, 2025, 4:20 PM EST - 8 months ago

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Nov 19, 2025, 8:30 AM EST - 8 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

2025-11-17T11:15:44.000Z - 8 months ago

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

Vivos Therapeutics announces additional data from use of Vivos DNA device

2025-09-30T12:45:33.000Z - 9 months ago

Vivos Therapeutics announces additional data from use of Vivos DNA device

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Sep 30, 2025, 8:30 AM EDT - 9 months ago

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Vivos Therapeutics Proxy statement: Proxy Filing

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Vivos Therapeutics Proxy statement: Proxy Filing

Vivos Therapeutics announces trial results in pediatric OSA treatment

2025-09-17T12:41:24.000Z - 10 months ago

Vivos Therapeutics announces trial results in pediatric OSA treatment

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Sep 17, 2025, 8:30 AM EDT - 10 months ago

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Vivos Therapeutics Registration statement: Registration Filing

Sep 5, 2025, 8:00 AM EDT - 10 months ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Earnings Call Transcript: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Earnings Call Transcript: Q2 2025

Vivos Therapeutics Earnings release: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Earnings release: Q2 2025

Vivos Therapeutics Quarterly report: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Quarterly report: Q2 2025

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 19, 2025, 4:20 PM EDT - 11 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP

2025-07-30T12:50:50.000Z - 1 year ago

Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP

Vivos Therapeutics receives Medicare approval for VidaSleep Oral Applicance

2025-07-01T12:40:14.000Z - 1 year ago

Vivos Therapeutics receives Medicare approval for VidaSleep Oral Applicance

Vivos announces results published of OSA using Daytime-Nighttime Appliance

2025-06-26T12:40:25.000Z - 1 year ago

Vivos announces results published of OSA using Daytime-Nighttime Appliance

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

Jun 26, 2025, 8:30 AM EDT - 1 year ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock

2025-06-11T12:35:17.000Z - 1 year ago

Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock

Vivos Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q1 2025

Vivos Therapeutics Earnings release: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q1 2025

Vivos Therapeutics Quarterly report: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Quarterly report: Q1 2025

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

May 14, 2025, 9:15 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Vivos Therapeutics Earnings Call Transcript: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q4 2024

Vivos Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q4 2024

Vivos Therapeutics Annual report: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Annual report: Q4 2024

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Vivos Therapeutics Transcript: Fireside Chat

Feb 18, 2025, 12:00 PM EST - 1 year ago

Vivos Therapeutics Transcript: Fireside Chat

Vivos Therapeutics Registration statement: Registration Filing

Feb 11, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Registration statement: Registration Filing

Jan 22, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 8:00 AM EST - 1 year ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Vivos Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q3 2024

Vivos Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings release: Q3 2024

Vivos Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Quarterly report: Q3 2024

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Nov 13, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Sep 18, 2024, 7:00 AM EDT - 1 year ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q2 2024

Vivos Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Quarterly report: Q2 2024

Vivos Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q2 2024

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Aug 14, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Registration statement: Registration Filing

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Jun 12, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Vivos Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q1 2024

Vivos Therapeutics Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Quarterly report: Q1 2024

Vivos Therapeutics Earnings release: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q1 2024

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

May 14, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Registration statement: Registration Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Registration statement: Registration Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q4 2023

Vivos Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q4 2023

Vivos Therapeutics Annual report: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Annual report: Q4 2023

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Mar 28, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Feb 6, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Jan 8, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Dec 11, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Vivos Therapeutics Registration statement: Registration Filing

Nov 30, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 11:09 AM EST - 2 years ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:44 AM EST - 2 years ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 29, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Vivos Therapeutics Registration statement: Registration Filing

Nov 22, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Vivos Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q3 2023

Vivos Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Quarterly report: Q3 2023

Vivos Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings release: Q3 2023

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 14, 2023, 4:05 PM EST - 2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 9, 2023, 4:30 PM EST - 2 years ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics Closes $4 Million Private Placement

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement

Giovannirs3
Giovannirs3 Jul. 4 at 12:58 PM
$VVOS 🤡
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:26 AM
$VVOS 👀👌👌👍🤣🤣🤗👎👍👍
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:25 AM
$VVOS 🤣🤣🤣🤣🤣🤣🤣🤗🤗🤗🤗
0 · Reply
Giovannirs3
Giovannirs3 Jul. 4 at 10:25 AM
$VVOS 👇👇🤣🤣🤣🤣🤣🤣🤣🚆🚆🚆🚆🚆
0 · Reply
kemsma62
kemsma62 Jul. 3 at 2:01 PM
$VVOS 🚀🧨🔥 The future belongs to $VVOS!
1 · Reply
Giovannirs3
Giovannirs3 Jul. 3 at 8:46 AM
$VVOS 💔
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡🤡🤡🤡🤡9️⃣❤️
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡🤡👎
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 🤡
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 👎
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 10:54 PM
$VVOS 👍
0 · Reply
Loopi
Loopi Jul. 2 at 8:36 PM
$VVOS Next targets are $0.22 >> $0.12 🔴🔜
0 · Reply
Peaceouty
Peaceouty Jul. 2 at 8:03 PM
$VVOS Promising break even since Q2 2023! Yet continues to loose even more with the same revenues. Amazing.
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 7:58 PM
$VVOS 🤗👌🤗
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 7:58 PM
$VVOS 👌👌👎
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 7:58 PM
$VVOS 🤗
0 · Reply
Loopi
Loopi Jul. 2 at 6:53 PM
$VVOS waiting for RS 🗑️🔜🔴🔴
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 6:53 PM
$VVOS 👌
0 · Reply
AHMA96674
AHMA96674 Jul. 2 at 6:14 PM
$VVOS hmm
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 5:49 PM
$VVOS 🤗
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 5:48 PM
$VVOS 18753
0 · Reply
Giovannirs3
Giovannirs3 Jul. 2 at 5:47 PM
$VVOS 💔👀🤗
0 · Reply